



Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008

November 6, 2008

- 3Q and nine month 2008 total revenues increased 30 and 53 percent, respectively, over comparable prior year periods
- 3Q 2008 net income of \$10.4 million, or \$0.35 per share, represents an increase of 265 percent over prior year
- Nine month 2008 net income of \$19.2 million, or \$0.65 per share, as compared to a net loss of \$4.8 million, or \$0.17 per share, in prior year
- September 30, 2008 cash and cash equivalents of \$104.7 million
- 2008 financial guidance updated--revenue range maintained at \$180 to \$195 million, net income revised upward to \$21 to \$25 million, or \$0.70 to \$0.83 per basic share

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 6, 2008--Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the third quarter and nine months ended September 30, 2008.

Total revenues for the third quarter and nine months of 2008 were \$56.6 million and \$142.8 million, respectively, an increase of 30 percent and 53 percent, respectively, over the prior year periods. Net income for the third quarter and nine months of 2008 was \$10.4 million or \$0.35 per share, and \$19.2 million or \$0.65 per share, respectively, in comparison to net income of \$2.8 million or \$0.10 per share, and a net loss of \$4.8 million or \$0.17 per share for the comparable periods in 2007. Such performance was primarily driven by growth in sales of BioThrax(R) (Anthrax Vaccine Adsorbed), the company's FDA licensed vaccine for the prevention of anthrax.

R. Don Elsey, Emergent BioSolutions' chief financial officer, said, "Our financial performance as reported today positions us well to achieve our objectives for year over year revenue growth and year end profitability. In addition, our recently signed contract with HHS for the delivery of 14.5 million additional doses of BioThrax for inclusion in the SNS provides us with revenue visibility through 3Q 2011. This contract coupled with recently executed development agreements with the U.S. government allows us to position the company for continued growth through both acquisitions and progress in our product development programs. We have been able to advance our product pipeline candidates and add exciting new candidates and collaborations while tightly managing spending. In summary, the strength of our operations and our ability to effectively manage our business in pursuit of our strategic initiatives remains well on track to achieving our objective of a seventh consecutive year of profitable operations."

3Q 2008 Highlights:

- Signed a follow on contract for 14.5 million additional doses of BioThrax with HHS valued at up to \$404 million, offering revenue visibility through 3Q 2011; this is beyond last year's contract of up to \$448 million to deliver 18.75 million doses of BioThrax through 3Q 2009;
- Submitted to HHS a proposal in response to a RFP for development and procurement of a second generation anthrax vaccine, which was subsequently deemed technically acceptable and within the competitive range;
- Secured up to \$58.5 million of government development contracts and grants to fund future work on selected anthrax and botulism product candidates; and
- Formed joint venture with the University of Oxford to develop an advanced tuberculosis vaccine, with funding from Wellcome Trust and Aeras Global TB Vaccine Foundation.

Product Sales

For the third quarter of 2008, product sales, which consisted of sales of BioThrax to HHS, increased by \$13.7 million, or 33 percent, to \$55.5 million from \$41.8 million for the comparable period of 2007. This increase was primarily due to a 34 percent increase in the average sales price per dose.

For the nine month period of 2008, product sales increased by \$49.6 million, or 55 percent, to \$139.3 million from \$89.8 million for the comparable period of 2007, primarily due to a 36 percent increase in the number of doses of BioThrax sold and a 14 percent increase in the average sales price per dose. Product sales for the nine month period of 2008 consisted of BioThrax sales to HHS of \$138.5 million and aggregate international and other sales of \$0.8 million.

Contracts and Grants Revenues

For the third quarter of 2008, contracts and grants revenues decreased by \$0.7 million, or 40 percent, to \$1.1 million from \$1.9 million for the comparable period of 2007. Contracts and grants revenues for the third quarter of 2008 consisted of \$0.5 million from our meningitis vaccine collaboration and \$0.7 million from the National Institute of Allergy and Infectious Diseases (NIAID) and other U.S. governmental agencies.

For each of the nine month periods of 2008 and 2007, contracts and grants revenues were \$3.5 million. Contracts and grants revenues for the nine month period of 2008 consisted of \$2.0 million from our meningitis collaboration as well as development service revenue from the meningitis vaccine collaboration, and \$1.5 million from NIAID and other governmental agencies.

Cost of Product Sales

For the third quarter of 2008, cost of product sales decreased by \$0.9 million, or 8 percent, to \$10.5 million from \$11.4 million for the comparable period of 2007, primarily attributable to decreased costs associated with improved production yield. For the nine month period of 2008, cost of product sales increased by \$4.4 million, or 20 percent, to \$27.2 million from \$22.8 million for the comparable period in 2007, attributable to a 36 percent increase in the number of doses of BioThrax sold, partially offset by decreased costs associated with improved production yield.

Research and Development

For the third quarter of 2008, research and development expenses increased by \$3.9 million, or 30 percent, to \$16.6 million from \$12.8 million for the comparable period of 2007. This increase reflects higher contract service costs and asset and technology acquisition costs, and includes increased expenses of \$2.1 million on product candidates that are categorized in the biodefense segment, \$1.1 million on product candidates categorized in the commercial segment and \$0.6 million in other research and development expenses, which are in support of technology platforms and central research and development activities.

For the nine month period of 2008, research and development expenses increased by \$3.6 million, or 9 percent, to \$45.3 million from \$41.7 million for the comparable period of 2007. This increase reflects higher contract service costs, and includes increased expenses of \$3.4 million on product candidates categorized in the commercial segment and \$1.3 million in other research and development expenses, partially offset by decreased expenses of \$1.1 million on product candidates that are categorized in the biodefense segment.

Selling, General and Administrative

For the third quarter of 2008, selling, general and administrative expenses decreased by \$0.9 million, or 6 percent, to \$14.1 million from \$15.0 million for the comparable period of 2007. This decrease was primarily driven by lower costs in our headquarters and staff organization and primarily reflects a decrease of approximately \$1.0 million resulting from decreased professional services for our headquarters organization, offset by an increase of \$0.1 million in sales and marketing expenses related to the growth of our staff and an increase in our sales and marketing activities.

For the nine month period of 2008, selling, general and administrative expenses increased by \$2.3 million, or 6 percent, to \$41.2 million from \$38.9 million for the comparable period of 2007. This increase was primarily driven by an increase in our headquarters and staff organization to support the overall growth of our business, and primarily reflects an increase of approximately \$1.8 million resulting from the addition of personnel and increased legal and other professional services for our headquarters organization and an increase of \$0.5 million in sales and marketing expenses related to the growth of our staff and an increase in our sales and marketing activities.

Financial Condition and Liquidity

Cash and cash equivalents at September 30, 2008 was \$104.7 million compared to \$105.7 million at December 31, 2007. The net decrease in cash and cash equivalents resulted primarily from net cash provided by operating activities and financing activities of \$19.3 million and \$6.1 million, respectively, offset by net cash used in investing activities of \$26.5 million.

Financial Outlook for 2008

In light of the performance through the nine months of 2008, the company is updating its financial outlook for 2008. Specifically, management continues to anticipate full year total revenues of between \$180 and \$195 million. In addition, management is revising upwards its expectations for full year net income of between \$21 and \$25 million, or between \$0.70 and \$0.83 per basic share. Importantly, these projections do not reflect the potential acquisition of Protein Sciences Corporation.

Conference Call & Webcast

Company management will host a conference call at 4:30 pm Eastern on November 6, 2008 to discuss these financial results, recent business developments and the outlook for the remainder of 2008. The conference call will be accessible by dialing 888/680-0879 or 617/213-4856 (international) and providing passcode 22722030. A webcast of the conference call will be accessible from the Company's website at www.emergentbiosolutions.com, under "Investors".

A replay of the conference call will be accessible, approximately one hour following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 80179182. The replay will be available through November 20. The webcast will be archived on the company's website.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission--to protect life. Emergent develops, manufactures and commercializes immune-related biologics, vaccines and therapeutics that assist the body's immune system to prevent or treat infectious and other life threatening diseases. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's clinical pipeline includes programs focused on anthrax, botulism, typhoid, tuberculosis, hepatitis B and chlamydia. www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including our expected revenue growth and net earnings for 2008, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain new BioThrax(R) sales contracts with the U.S. government; our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing

collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company's current report on Form 10-Q for the quarter ended June 30, 2008 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Financial Statements Follow

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)

	Three Months Ended September 30,	
	2008	2007
	(unaudited)	
Revenues:		
Product sales	\$ 55,478	\$ 41,786
Contracts and grants	1,121	1,858
Total revenues	56,599	43,644
Operating expense:		
Cost of product sales	10,519	11,407
Research and development	16,627	12,777
Selling, general and administrative	14,115	15,038
Income from operations	15,338	4,422
Other income (expense):		
Interest income	476	472
Interest expense	2	(7)
Other income (expense), net	(1)	(14)
Total other income (expense)	477	451
Minority interest in subsidiary	428	-
Income before provision for income taxes	16,243	4,873
Provision for income taxes	5,857	2,028
Net income	\$ 10,386	\$ 2,845
Earnings per share -- basic	\$ 0.35	\$ 0.10
Earnings per share -- diluted	\$ 0.34	\$ 0.10
Weighted-average number of shares -- basic	29,819	29,740
Weighted-average number of shares -- diluted	30,591	29,901

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)

Nine Months Ended

	September 30,	
	2008	2007
	(unaudited)	
Revenues:		
Product sales	\$ 139,308	\$ 89,750
Contracts and grants	3,496	3,528
Total revenues	142,804	93,278
Operating expense:		
Cost of product sales	27,211	22,765
Research and development	45,308	41,689
Selling, general and administrative	41,212	38,889
Income (loss) from operations	29,073	(10,065)
Other income (expense):		
Interest income	1,598	1,945
Interest expense	(4)	(54)
Other income (expense), net	183	164
Total other income (expense)	1,777	2,055
Minority interest in subsidiary	428	-
Income (loss) before provision for (benefit from) income taxes	31,278	(8,010)
Provision for (benefit from) income taxes	12,051	(3,205)
Net income (loss)	\$ 19,227	\$ (4,805)
Earnings (loss) per share -- basic	\$ 0.65	\$ (0.17)
Earnings (loss) per share -- diluted	\$ 0.64	\$ (0.17)
Weighted-average number of shares -- basic	29,778	28,741
Weighted-average number of shares -- diluted	30,152	28,741

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share data)

	September 30, December 31,	
	2008	2007
	(unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 104,688	\$ 105,730
Accounts receivable	14,070	18,817
Inventories	17,516	16,897
Note receivable	10,000	-
Prepaid expenses and other current assets	5,700	2,866
Total current assets	151,974	144,310
Property, plant and equipment, net	120,898	110,218

Deferred tax assets, net	12,598	12,397
Restricted cash	200	5,200
Other assets	1,726	1,383
	-----	-----
Total assets	\$ 287,396	\$ 273,508
	-----	-----
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 16,673	\$ 20,257
Accrued expenses and other current liabilities	1,463	1,778
Accrued compensation	10,378	9,502
Indebtedness under line of credit	15,000	11,832
Long-term indebtedness, current portion	3,739	3,514
Income taxes payable	2,898	7,665
Deferred tax liabilities, net	597	211
Deferred revenue, current portion	820	902
	-----	-----
Total current liabilities	51,568	55,661
	-----	-----
Long-term indebtedness, net of current portion	39,651	42,588
Deferred revenue, net of current portion	1,853	2,473
Other liabilities	1,495	1,627
	-----	-----
Total liabilities	94,567	102,349
	-----	-----
Commitments and contingencies	-	-
Stockholders' equity:		
Preferred Stock, \$0.001 par value; 15,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2008 and December 31, 2007	-	-
Common Stock, \$0.001 par value; 100,000,000 shares authorized; 29,850,411 and 29,750,237 shares issued and outstanding at September 30, 2008 and December 31, 2007, respectively	30	30
Additional paid-in capital	104,288	101,933
Accumulated other comprehensive loss	(1,040)	(1,130)
Retained earnings	89,551	70,326
	-----	-----
Total stockholders' equity	192,829	171,159
	-----	-----
Total liabilities and stockholders' equity	\$ 287,396	\$ 273,508
	-----	-----

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)

	Nine Months Ended September 30,	
	2008	2007

	(unaudited)	
Cash flows from operating activities:		
Net income (loss)	\$ 19,227	\$ (4,805)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating		

activities:		
Stock-based compensation expense	1,733	1,895
Depreciation and amortization	3,547	3,597
Deferred income taxes	185	9,418
Gain on disposal of property and equipment	(182)	-
Excess tax benefits from stock-based compensation	-	(6,708)
Minority interest in subsidiary	(428)	-
Changes in operating assets and liabilities:		
Accounts receivable	4,747	1,318
Inventories	(619)	(901)
Income taxes	(4,767)	(25,820)
Prepaid expenses and other assets	(2,749)	(1,109)
Accounts payable	(1,165)	1,521
Accrued expenses and other liabilities	876	(1,512)
Accrued compensation	(447)	426
Deferred revenue	(702)	(1,015)
	-----	-----
Net cash provided by (used in) operating activities	19,256	(23,695)
	-----	-----
Cash flows from investing activities:		
Purchases of property, plant and equipment	(16,464)	(36,197)
Issuance of note receivable	(10,000)	-
	-----	-----
Net cash used in investing activities	(26,464)	(36,197)
	-----	-----
Cash flows from financing activities:		
Proceeds from borrowings on long term indebtedness and line of credit	45,000	15,333
Issuance of common stock subject to exercise of stock options	620	2,474
Principal payments on long term indebtedness and line of credit	(44,544)	(11,131)
Excess tax benefits from stock-based compensation	-	6,708
Restricted cash release (deposit)	5,000	(5,000)
	-----	-----
Net cash provided by financing activities	6,076	8,384
	-----	-----
Effect of exchange rate changes on cash and cash equivalents	90	(644)
	-----	-----
Net decrease in cash and cash equivalents	(1,042)	(52,152)
Cash and cash equivalents at beginning of period	105,730	76,418
	-----	-----
Cash and cash equivalents at end of period	\$104,688	\$ 24,266
	-----	-----

CONTACT: Emergent BioSolutions Inc.

Investors:

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

BurrowsR@ebsi.com

or

Media:

Kimberly B. Root

Director, Public Affairs

517-327-1543

(m) 517-749-3265

RootK@ebsi.com

SOURCE: Emergent BioSolutions Inc.